Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07597902

SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction

The purpose of this research study is to test if the combination of three drugs, valacyclovir, celecoxib, and Paxlovid will decrease the symptoms of Long COVID in adults compared to a placebo (this does not contain the medications).

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

The Cohen Center for Recovery from Complex Chronic Illnesses (CoRE)

New York, 10029, United States

Location contact

David Putrino, PhD

PRINCIPAL_INVESTIGATOR

CONTACT

[email protected]

About this study

This is an off-label, randomized, double-blind, active placebo-controlled, two-arm clinical trial of a combination of celecoxib, valacyclovir, and Paxlovid in adults with Long COVID. This study aims to evaluate the safety and efficacy of the combination of celecoxib, valacyclovir, and Paxlovid in adults with Long COVID (LC). Safety will be primarily measured through blood and urine measures. Efficacy will be evaluated by measuring patient-reported outcomes.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18-65 years of age at the time of study entry
  • Diagnosed with Long COVID
  • Individuals of child-bearing potential must have a negative serum pregnancy test at screening and agree to on-site urine pregnancy testing at all subsequent study visits
  • A urine drug screen performed at the Screening Visit must be negative for drugs of abuse such as methamphetamine, cocaine, phencyclidine (PCP), and non-disclosed amphetamines and opioids/opiates.
  • Those with mild to moderate depression should be clinically stable for three months, without risk of suicidal ideation or behavior.

Exclusion criteria

  • Breastfeeding, pregnant, or planning to become pregnant during the next six months.
  • In the opinion of the Investigator, any clinically significant, uncontrolled, or unstable medical or surgical condition that could affect the individual's ability to participate in the study or potentially compromise their well-being while enrolled in the study.
  • In the opinion of the Investigator or based on results of the HADS, evidence of a clinically significant psychiatric disorder, e.g., severe, unstable or poorly controlled depression, anxiety or obsessive-compulsive disorder; moderate or severe alcohol use disorder; substance use disorder other than mild cannabis use disorder; or any history of bipolar disorder, schizophrenia, schizoaffective disorder or other psychotic disorder.
  • Currently meeting criteria for ME/CFS at the pre-screening or screening visit, or a prior confirmed diagnosis of ME/CFS within the last 5 years. This may be determined as part of the initial screening call or visit.
  • Any anticipated need for surgery that in the opinion of the Principal Investigator or Sub-I might confound results or interfere with the participant's ability to comply with the protocol.
  • Symptomatic and/or otherwise clinically significant cardiac disease
  • Acute non-COVID systemic infection (e.g., HIV, hepatitis) or other active viral or bacterial infection during the screening/washout period or at the Baseline visit.
  • Currently receiving chronic systemic corticosteroids (>5 mg prednisone daily, or equivalent)
  • Routine treatment with warfarin, heparin, lithium, digoxin, amiodarone, isoniazid, phenytoin, fluconazole, methotrexate, probenecid, or raloxifene. Participants on these medications should not be screened.
  • Uncontrolled sleep apnea.
  • Use of chronic nucleoside analog antiviral suppression therapy within one month of the Screening Visit or requiring on average more than one acute treatment course every two months.
  • Current use of celecoxib either alone or in combination with valacyclovir or famciclovir
  • In the opinion of the Investigator, evidence of current drug or alcohol abuse or dependency, or history of abuse or dependence during the preceding 12 months.
  • The participant has undergone a malabsorptive weight loss procedure (e.g., Roux-en-Y or other bypass procedure).
  • Severe IBS-C or colonic inertia as evidenced by seven or more days between bowel movements.

Treatment and study plan

Valacyclovir

Drug

one to two 750mg capsules taken orally in the morning and evening

Celecoxib

Drug

200mg capsules taken orally in the morning and evening

Paxlovid

Drug

one (100mg ritonavir tablet and two 150mg nirmatrelvir tablets) taken orally in the morning and evening

Placebo

Drug

matching placebo capsules and tablets taken orally in the morning and evening

Primary outcomes

  1. EQ-5D-5L Visual Analogue Scale (VAS)

    Time frame: Baseline (Week 1), Week 4, Week 8, Week 12, Week 16, Week 20

    The EQ VAS records the patient's self-rated health on a visual analogue scale where the endpoints are labelled 'The best health you can imagine' (100) and 'The worst health you can imagine' (0), with higher scores indicating better health state. The VAS can be used as a quantitative measure of health outcome that reflects the patient's own judgement.

Secondary outcomes

  1. The EuroQol Five-Dimensional Health Questionnaire (EQ-5D-5L)

    Time frame: Baseline (Week 1), Week 4, Week 8, Week 12, Week 16, Week 20

    The EQ-5D-5L is a validated, standardized, generic instrument that is a preference-based health- related quality of life questionnaire. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate their health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. Full scale from 5 to 25, with higher score indicating poorer health outcomes.

  2. Patient-Reported Outcomes Measurement Information System 29 (PROMIS-29)

    Time frame: Baseline (Week 1), Week 4, Week 8, Week 12, Week 16, Week 20

    The PROMIS-29 v2.0 profile assesses pain intensity using a single 0-10 numeric rating item and seven health domains (physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance) using four items per domain. The values of all item responses are averaged to generate subscores for each dimension. From these subscores, a global physical health score and a global mental health score are generated. The scores are translated into T-scores according to a reference population with a mean of 50 and a standard deviation of 10.

  3. General Symptom Questionnaire (GSQ-30)

    Time frame: Baseline (Week 1), Week 4, Week 8, Week 12, Week 16, Week 20

    The General Symptom Questionnaire-30 (GSQ-30) is a valid and reliable instrument to assess symptom burden among patients with acute and post-treatment. The GSQ-30 total score ranges from 0 to 120, with higher scores indicating a greater symptom burden.

  4. Patient Health Questionnaire (PHQ-9)

    Time frame: Baseline (Week 1), Week 4, Week 8, Week 12, Week 16, Week 20

    The PHQ-9 is a series of questions assessing presence and severity of depression symptoms. It evaluates each of the DSM-IV depression criteria and scores the responses from 0 ("Not at all") to 3 ("Nearly every day"). PHQ-9 scores of 5, 10, 15, and 20 represented mild, moderate, moderately severe, and severe depression, respectively. Full scale from 0-27, with higher score indicating more severe symptoms.

  5. Generalized Anxiety Disorder (GAD-7)

    Time frame: Baseline (Week 1), Week 4, Week 8, Week 12, Week 16, Week 20

    The GAD-7 is a 7-item scale developed and validated to identify generalized anxiety disorder and its severity. It assesses the frequency of 7 anxiety symptoms and scores the responses from 0 ("Not at all") to 3 ("Nearly every day"). Total scores of 5, 10, and 15 correspond to mild, moderate, and severe generalized anxiety disorder, respectively. Full scale from 0-21, with higher score indicating more symptoms.

  6. COLUMBIA-SUICIDE SEVERITY RATING SCALE (C-SSRS)

    Time frame: Baseline (Week 1), Week 4, Week 8, Week 12, Week 16, Week 20

    A suicide risk assessment tool that supports suicide risk assessment through a series of simple, plain-language questions that anyone can ask. The answers help users identify whether someone is at risk for suicide, assess the severity and immediacy of that risk, and gauge the level of support that the person needs.

    Full range from 0 (low intensity suicidal ideation to 9 (high intensity suicidal ideation). Higher score represents poorer health outcomes.

  7. Neuro-QoL™ v2.0 Cognitive Function-Short Form

    Time frame: Baseline (Week 1), Week 4, Week 8, Week 12, Week 16, Week 20

    The Neuro-QoL Cognitive Function v2.0 short form assesses perceived difficulties in cognitive abilities, including memory, attention, decision making, planning, organizing, calculating, remembering, and learning. The short form consists of 8 questions assessed on a 5-point Likert scale, resulting in a raw score range of 8 to 40. A raw score is then converted to a T-score using conversion tables. Scores 0.5 - 1.0 SD worse than the mean (T-score 40-45) = mild symptoms/impairment. Scores 1.0 - 2.0 SD worse than the mean (T-score 30-40) = moderate symptoms/impairment. Scores 2.0 SD or more worse than the mean (T-score below 30) = severe symptoms/impairment.

  8. Single-item Sleep Quality Scale (SQS)

    Time frame: Baseline (Week 1), Week 4, Week 8, Week 12, Week 16, Week 20

    The SQS is a visual analog scale that instructs respondents to rate their overall quality of sleep over a 7-day recall period from 0 to 10. Scores of 0, 1, 4, 7, and 10 correspond to terrible, poor, fair, good, and excellent, respectively. Higher scores indicate better sleep quality.

Study contacts

Contact information is provided by the study sponsor or research team.

David Putrino, PhD

CONTACT

[email protected]

212-241-7658

Sponsors and collaborators

Lead sponsor

Icahn School of Medicine at Mount Sinai

Other

Registry information

Official study title

SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction (SHIELD)

Acronym: SHIELD

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
May 19, 2026
Registry last updated
May 19, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.